Advertisement

Topics

Atypical Chemokine Receptor 3 CXC Chemokine Receptor Type 7 or Chemokine Orphan Receptor 1 or G Protein Coupled Receptor 159 or G Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7 or ACKR3 Pipeline Review, H1 2018 [Report Updated: 17042018] Prices

01:52 EDT 12 Aug 2018 | BioPortfolio Reports

Atypical Chemokine Receptor 3 CXC Chemokine Receptor Type 7 or Chemokine Orphan Receptor 1 or G Protein Coupled Receptor 159 or G Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7 or ACKR3 Pipeline Review, H1 2018


Summary


Atypical Chemokine Receptor 3 CXC Chemokine Receptor Type 7 or Chemokine Orphan Receptor 1 or G Protein Coupled Receptor 159 or G Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7 or ACKR3 pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.


The latest report Atypical Chemokine Receptor 3 Pipeline Review, H1 2018, outlays comprehensive information on the Atypical Chemokine Receptor 3 CXC Chemokine Receptor Type 7 or Chemokine Orphan Receptor 1 or G Protein Coupled Receptor 159 or G Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7 or ACKR3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.


Atypical Chemokine Receptor 3 CXC Chemokine Receptor Type 7 or Chemokine Orphan Receptor 1 or G Protein Coupled Receptor 159 or G Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7 or ACKR3 Atypical chemokine receptor 3 is a protein encoded by the ACKR3 gene.


It controls chemokine levels and localization via highaffinity chemokine binding that is uncoupled from classic liganddriven signal transduction cascades, resulting instead in chemokine sequestration, degradation, or transcytosis. It acts as a receptor for chemokines CXCL11 and CXCL12/SDF1. Chemokine binding does not activate Gproteinmediated signal transduction but instead induces betaarrestin recruitment, leading to ligand internalization and activation of MAPK signaling pathway.


It is required for regulation of CXCR4 protein levels in migrating interneurons, thereby adapting their chemokine responsiveness. The molecules developed by companies in Preclinical and Discovery stages are 3 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively.


Report covers products from therapy areas Oncology, Cardiovascular, Gastrointestinal and Musculoskeletal Disorders which include indications Atherosclerosis, Crohn's Disease Regional Enteritis, Fibrosis, Glioblastoma Multiforme GBM, Multiple Myeloma Kahler Disease, Solid Tumor and Vascular Injury.


Furthermore, this report also reviews key players involved in Atypical Chemokine Receptor 3 CXC Chemokine Receptor Type 7 or Chemokine Orphan Receptor 1 or G Protein Coupled Receptor 159 or G Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7 or ACKR3 targeted therapeutics development with respective active and dormant or discontinued projects.


Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Atypical Chemokine Receptor 3 CXC Chemokine Receptor Type 7 or Chemokine Orphan Receptor 1 or G Protein Coupled Receptor 159 or G Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7 or ACKR3

The report reviews Atypical Chemokine Receptor 3 CXC Chemokine Receptor Type 7 or Chemokine Orphan Receptor 1 or G Protein Coupled Receptor 159 or G Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7 or ACKR3 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Atypical Chemokine Receptor 3 CXC Chemokine Receptor Type 7 or Chemokine Orphan Receptor 1 or G Protein Coupled Receptor 159 or G Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7 or ACKR3 targeted therapeutics and enlists all their major and minor projects

The report assesses Atypical Chemokine Receptor 3 CXC Chemokine Receptor Type 7 or Chemokine Orphan Receptor 1 or G Protein Coupled Receptor 159 or G Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7 or ACKR3 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Atypical Chemokine Receptor 3 CXC Chemokine Receptor Type 7 or Chemokine Orphan Receptor 1 or G Protein Coupled Receptor 159 or G Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7 or ACKR3 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Atypical Chemokine Receptor 3 CXC Chemokine Receptor Type 7 or Chemokine Orphan Receptor 1 or G Protein Coupled Receptor 159 or G Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7 or ACKR3

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Atypical Chemokine Receptor 3 CXC Chemokine Receptor Type 7 or Chemokine Orphan Receptor 1 or G Protein Coupled Receptor 159 or G Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7 or ACKR3 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Atypical Chemokine Receptor 3 CXC Chemokine Receptor Type 7 or Chemokine Orphan Receptor 1 or G Protein Coupled Receptor 159 or G Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7 or ACKR3 Pipeline Review, H1 2018 [Report Updated: 17042018] Prices

NEXT ARTICLE

More From BioPortfolio on "Atypical Chemokine Receptor 3 CXC Chemokine Receptor Type 7 or Chemokine Orphan Receptor 1 or G Protein Coupled Receptor 159 or G Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7 or ACKR3 Pipeline Review, H1 2018 [Report Updated: 17042018] Prices"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cytokine
Cytokines include chemokines, lymphokines, and monokines. Cells of the immune system communicate with one another by releasing and responding to chemical messengers called cytokines. These proteins are secreted by immune cells and act on other cells to...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...